{"id":21003,"date":"2025-01-08T19:49:47","date_gmt":"2025-01-08T11:49:47","guid":{"rendered":"https:\/\/flcube.com\/?p=21003"},"modified":"2025-01-08T19:49:48","modified_gmt":"2025-01-08T11:49:48","slug":"bayers-nubeqa-seeks-nmpa-approval-for-new-prostate-cancer-indication","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21003","title":{"rendered":"Bayer’s Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication"},"content":{"rendered":"\n

Bayer AG (ETR: BAYN<\/a>) has announced the submission of a supplemental new drug application (sNDA) for its Nubeqa (darolutamide) to the National Medical Products Administration (NMPA) in China. The German pharmaceutical giant is seeking approval for its androgen receptor inhibitor (ARi) combined with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). This marks the third indication filing for the drug in China.<\/p>\n\n\n\n

Previous Approvals and Study Results<\/strong>
Nubeqa was previously approved in China for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) with a high risk of metastasis and for mHSPC when combined with docetaxel in February 2021 and May 2023, respectively. The latest filing is supported by positive results from the Phase III ARANOTE study, which assessed the efficacy and safety of darolutamide combined with ADT in mHSPC.<\/p>\n\n\n\n

Study Details and Findings<\/strong>
The ARANOTE study, co-developed by Finnish pharma Orion Corporation, recruited a total of 669 patients. The results showed that the darolutamide\/ADT combination significantly improved radiographic progression-free survival (rPFS) compared to placebo combined with ADT. Additionally, the treatment emergent adverse events (TEAEs) rate was lower in patients treated with the darolutamide\/ADT combination, confirming its safety profile consistent with previous findings.<\/p>\n\n\n\n

Significance of the Application<\/strong>
The submission of the sNDA underscores Bayer’s commitment to expanding the therapeutic applications of Nubeqa and providing more treatment options for patients with prostate cancer. This development highlights the potential of Nubeqa to improve patient outcomes and enhance the management of metastatic hormone-sensitive prostate cancer.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Bayer AG (ETR: BAYN) has announced the submission of a supplemental new drug application (sNDA)…<\/p>\n","protected":false},"author":1,"featured_media":21004,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[269,967,38],"class_list":["post-21003","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-bayer","tag-etr-bayn","tag-market-approval-filings"],"yoast_head":"\nBayer's Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bayer AG (ETR: BAYN) has announced the submission of a supplemental new drug application (sNDA) for its Nubeqa (darolutamide) to the National Medical Products Administration (NMPA) in China. The German pharmaceutical giant is seeking approval for its androgen receptor inhibitor (ARi) combined with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). This marks the third indication filing for the drug in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21003\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer's Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication\" \/>\n<meta property=\"og:description\" content=\"Bayer AG (ETR: BAYN) has announced the submission of a supplemental new drug application (sNDA) for its Nubeqa (darolutamide) to the National Medical Products Administration (NMPA) in China. The German pharmaceutical giant is seeking approval for its androgen receptor inhibitor (ARi) combined with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). This marks the third indication filing for the drug in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21003\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-08T11:49:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-08T11:49:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0824.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"420\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21003#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21003\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer’s Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication\",\"datePublished\":\"2025-01-08T11:49:47+00:00\",\"dateModified\":\"2025-01-08T11:49:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21003\"},\"wordCount\":263,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21003#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0824.png\",\"keywords\":[\"Bayer\",\"ETR: BAYN\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21003#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21003\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21003\",\"name\":\"Bayer's Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21003#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21003#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0824.png\",\"datePublished\":\"2025-01-08T11:49:47+00:00\",\"dateModified\":\"2025-01-08T11:49:48+00:00\",\"description\":\"Bayer AG (ETR: BAYN) has announced the submission of a supplemental new drug application (sNDA) for its Nubeqa (darolutamide) to the National Medical Products Administration (NMPA) in China. The German pharmaceutical giant is seeking approval for its androgen receptor inhibitor (ARi) combined with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). This marks the third indication filing for the drug in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21003#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21003\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21003#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0824.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0824.png\",\"width\":1080,\"height\":420,\"caption\":\"Bayer's Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21003#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer’s Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer's Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication - Insight, China's Pharmaceutical Industry","description":"Bayer AG (ETR: BAYN) has announced the submission of a supplemental new drug application (sNDA) for its Nubeqa (darolutamide) to the National Medical Products Administration (NMPA) in China. The German pharmaceutical giant is seeking approval for its androgen receptor inhibitor (ARi) combined with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). This marks the third indication filing for the drug in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21003","og_locale":"en_US","og_type":"article","og_title":"Bayer's Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication","og_description":"Bayer AG (ETR: BAYN) has announced the submission of a supplemental new drug application (sNDA) for its Nubeqa (darolutamide) to the National Medical Products Administration (NMPA) in China. The German pharmaceutical giant is seeking approval for its androgen receptor inhibitor (ARi) combined with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). This marks the third indication filing for the drug in China.","og_url":"https:\/\/flcube.com\/?p=21003","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-08T11:49:47+00:00","article_modified_time":"2025-01-08T11:49:48+00:00","og_image":[{"width":1080,"height":420,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0824.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21003#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21003"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer’s Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication","datePublished":"2025-01-08T11:49:47+00:00","dateModified":"2025-01-08T11:49:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21003"},"wordCount":263,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=21003#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0824.png","keywords":["Bayer","ETR: BAYN","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21003#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21003","url":"https:\/\/flcube.com\/?p=21003","name":"Bayer's Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=21003#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=21003#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0824.png","datePublished":"2025-01-08T11:49:47+00:00","dateModified":"2025-01-08T11:49:48+00:00","description":"Bayer AG (ETR: BAYN) has announced the submission of a supplemental new drug application (sNDA) for its Nubeqa (darolutamide) to the National Medical Products Administration (NMPA) in China. The German pharmaceutical giant is seeking approval for its androgen receptor inhibitor (ARi) combined with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). This marks the third indication filing for the drug in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21003#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21003"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=21003#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0824.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0824.png","width":1080,"height":420,"caption":"Bayer's Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21003#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer’s Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0824.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21003","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21003"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21003\/revisions"}],"predecessor-version":[{"id":21005,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21003\/revisions\/21005"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/21004"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21003"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21003"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21003"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}